Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Actelion_Pharmaceuticals_Ltd.
|
| gptkbp:activities |
prostacyclin receptor agonist
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:legislation
gptkb:2015 gptkb:United_States |
| gptkbp:brand |
gptkb:Uptravi
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
severe hepatic impairment
hypersensitivity to selexipag |
| gptkbp:developed_by |
gptkb:Actelion_Pharmaceuticals
|
| gptkbp:dosage_form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Selexipag
|
| gptkbp:indication |
treatment of pulmonary arterial hypertension
|
| gptkbp:ingredients |
gptkb:selexipag
C22 H26 N2 O4 S |
| gptkbp:is_used_for |
pulmonary arterial hypertension
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
oral medication
|
| gptkbp:pharmacokinetics |
bioavailability 100%
|
| gptkbp:side_effect |
headache
muscle pain nausea diarrhea jaw pain |
| gptkbp:type_of |
119576-90-5
|